Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
Marina Konopleva,Courtney DiNardo,Tushar Bhagat,Natalia Baran,Alessia Lodi,Kapil Saxena,Tianyu Cai,Xiaoping Su,Anna Skwarska,Veronica Guerra,Vinitha Kuruvilla,Sergej Konoplev,Shanisha Gordon-Mitchell,Kith Pradhan,Srinivas Aluri,Meghan Collins,Shannon Sweeney,Jonathan Busquet,Atul Rathore,Qing Deng,Michael Green,Steven Grant,Susan Demo,Gaurav Choudhary,Srabani Sahu,Beamon Agarwal,Mason Spodek,Victor Thiruthuvanathan,Britta Will,Ulrich Steidl,George Tippett,Jan Burger,Gautam Borthakur,Elias Jabbour,Naveen Pemmaraju,Tapan Kadia,Steven Komblau,Naval Daver,Kiran Naqvi,Nicholas Short,Guillermo Garcia-Manero,Stefano Tiziani,Amit Verma
DOI: https://doi.org/10.21203/rs.3.rs-2518774/v1
2023-02-23
Abstract:Malignancies can become reliant on glutamine as an alternative energy source and as a facilitator of aberrant DNA methylation, thus implicating glutaminase (GLS) as a potential therapeutic target. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective GLS inhibitor, when combined with azacytidine (AZA), in vitro and in vivo, followed by a phase Ib/II study of the combination in patients with advanced MDS. Treatment with telaglenastat/AZA led to an ORR of 70% with CR/mCRs in 53% patients and a median overall survival of 11.6 months. scRNAseq and flow cytometry demonstrated a myeloid differentiation program at the stem cell level in clinical responders. Expression of non-canonical glutamine transporter, SLC38A1, was found to be overexpressed in MDS stem cells; was associated with clinical responses to telaglenastat/AZA and predictive of worse prognosis in a large MDS cohort. These data demonstrate the safety and efficacy of a combined metabolic and epigenetic approach in MDS.